Sometimes, a single worry grows so large that it obscures all the good things happening at the same time. That’s the case with the stock of pharma giant AbbVie whose blockbuster drug Humira faces patent expirations.
Humira is an immunosuppressive that’s racked up nearly $200 billion in sales since its 2002 approval. AbbVie (ticker: ABBV) has fought fiercely to extend its exclusivity of Humira, which treats conditions from rheumatoid arthritis to Crohn’s disease, but it has already lost patent protection in Europe and faces increased competition from biosimilars in the U.S., beginning next year.
Source: finance.yahoo.com
Related posts:
UBS Says Wealthy Investors Are Hanging On to Cash
What Biden’s reported student debt cancellation plan could mean for borrowers
Palo Alto Networks Is Almost Profitable. Its Stock Is Too Cheap, Morgan Stanley Says.
Is AMD a Buy Following New Product Announcements? Wells Fargo Weighs In
Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.